PMID- 31837057
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210224
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Apr
TI  - The implication of LncRNA MALAT1 in promoting chemo-resistance of laryngeal 
      squamous cell carcinoma cells.
PG  - e23116
LID - 10.1002/jcla.23116 [doi]
LID - e23116
AB  - BACKGROUND: This study was aimed to evaluate the involvement of lncRNA MALAT1 in 
      modifying chemo-sensitivity of laryngeal squamous cell carcinoma (LSCC) cell 
      lines. METHODS: Totally 108 pairs of tumor tissues and matched para-tumor normal 
      tissues were gathered from patients who were pathologically confirmed as LSCC. 
      Meanwhile, LSCC cell lines, including TU686, TU177, AMC-HN-8, and LSC-1, were 
      purchased to evaluate their tolerance to cisplatin, 5-fluorouracil, paclitaxel, 
      and vincristine. Additionally, CCK-8 assay, flow cytometry, transwell assay, and 
      wound healing assay were implemented to assess the part of MALAT1 in modulating 
      viability, apoptosis, invasion, and migration of LSCC cell lines. RESULTS: MALAT1 
      expression was higher in LSCC tissues than in adjacent normal tissues (P < .05), 
      and LSCC patients who carried highly expressed MALAT1 demonstrated poorer 5-year 
      survival than ones with low MALAT1 expression (P < .05). For another, expression 
      of MALAT1 was also unusually elevated within TU686, TU177, AMC-HN-8, and LSC-1 
      cell lines as relative to NHBEC cell line (P < .05). The TU686 cell line therein 
      excelled in resisting the growth-curbing effects of 5-fluorouracil 
      (IC50 = 20.44 mumol/L), paclitaxel (IC50 = 35.86 mug/L), and vincristine 
      (IC50 = 0.12 mumol/L), when compared with TU177, AMC-HN-8, and LSC-1 cell line 
      (P < .05). Moreover, there seemed great potential for over-expressed MALAT1 to 
      enhance the chemo-resistance of both TU686 and LSC-1 cell lines (P < .05). Not 
      only that, silencing of MALAT1 tended to undermine the proliferative and 
      metastatic power of TU686 and LSC-1 cell lines (P < .05). CONCLUSION: LncRNA 
      MALAT1 counted in triggering tolerance of LSCC against chemo-drugs by boosting 
      metastasis and depressing apoptosis of tumor cells.
CI  - (c) 2019 The Authors. Journal of Clinical Laboratory Analysis published by Wiley 
      Periodicals, Inc.
FAU - Jiang, Qining
AU  - Jiang Q
AD  - Department of Radiotherapy, Guizhou Cancer Hospital & The Affiliated Cancer 
      Hospital of Guizhou Medical University, Guiyang, China.
FAU - Liu, Shiying
AU  - Liu S
AD  - Department of Radiotherapy, Guizhou Cancer Hospital & The Affiliated Cancer 
      Hospital of Guizhou Medical University, Guiyang, China.
FAU - Hou, Linna
AU  - Hou L
AD  - Department of Radiotherapy, Guizhou Cancer Hospital & The Affiliated Cancer 
      Hospital of Guizhou Medical University, Guiyang, China.
FAU - Guan, Yanfei
AU  - Guan Y
AD  - Department of Otolaryngology-Head and Neck Surgery, The First People's Hospital 
      of Yunnan Province, Kunming, China.
FAU - Yang, Shenggang
AU  - Yang S
AUID- ORCID: 0000-0001-5643-5212
AD  - Department of Radiotherapy, Yunnan Cancer Hospital & The Third Affiliated 
      Hospital of Kunming Medical University, Kunming, China.
FAU - Luo, Zhengyong
AU  - Luo Z
AD  - Department of Oncology, Puer People's Hospital, Puer, China.
LA  - eng
PT  - Journal Article
DEP - 20191214
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (MALAT1 long non-coding RNA, human)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Apoptosis/drug effects/genetics
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/*drug therapy/genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - RNA, Long Noncoding/*genetics
MH  - Squamous Cell Carcinoma of Head and Neck/*drug therapy/genetics/mortality
PMC - PMC7171298
OTO - NOTNLM
OT  - LncRNA MALAT1
OT  - chemo-sensitivity
OT  - epithelial-mesenchymal transition
OT  - laryngeal squamous cell carcinoma
EDAT- 2019/12/15 06:00
MHDA- 2021/02/25 06:00
PMCR- 2019/12/14
CRDT- 2019/12/15 06:00
PHST- 2019/09/17 00:00 [received]
PHST- 2019/10/17 00:00 [revised]
PHST- 2019/10/21 00:00 [accepted]
PHST- 2019/12/15 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
PHST- 2019/12/15 06:00 [entrez]
PHST- 2019/12/14 00:00 [pmc-release]
AID - JCLA23116 [pii]
AID - 10.1002/jcla.23116 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2020 Apr;34(4):e23116. doi: 10.1002/jcla.23116. Epub 2019 Dec 
      14.